Document:

Exhibit 10.6

 

 

September
20, 2022

 

3i,
LP

140
Broadway FL 38

New
York, NY 10005

 

Anson
Investments Master Fund LP

c/o
Anson Advisors Inc. 155 University Ave., Suite 207

Toronto,
ON Canada M5H3B7

 

Anson
East Master Fund LP

c/o
Anson Advisors Inc. 155 University Ave., Suite 207

Toronto,
ON Canada M5H3B7

 

	Re:	Modification
    of the Senior Secured Convertible Notes under the 2021 Purchase Agreement and certain other terms

 

Dear
Sirs:

 

Reference
is made to (a) that (i) certain Securities Purchase Agreement (as modified from time to time, the “2021 Purchase Agreement”),
dated as of September 24, 2021, between the Company and the purchasers identified therein, which are the same as the three addressees
listed above (collectively, the “2021 Investors”), (ii) the Senior Secured Convertible Promissory Notes (as modified
from time to time, the “2021 Senior Secured Convertible Notes”), (iii) the Warrants and (iv) the other transaction
documents, as modified from time to time, referred to collectively, as the “2021 Transaction Documents”) and (b) that
(i) certain Securities Purchase Agreement (as modified from time to time, the “2022 Purchase Agreement”), dated as
of June 30, 2022, between the Company and the purchasers identified therein, which are the same as the three addressees listed above
(collectively, the “2022 Investors”), (ii) the Senior Secured Convertible Promissory Notes (as modified from time
to time, the “2022 Senior Secured Convertible Notes”), (iii) the Warrants and (iv) the other transaction documents,
as modified from time to time, referred to collectively, as the “2022 Transaction Documents” and together with the
2021 Transaction Documents referred to as the “Transaction Documents”)). Capitalized terms used but not defined herein
shall have the meanings given to them in the applicable Purchase Agreement, or if not defined therein, in the applicable Notes, or if
not defined therein, in the applicable Transaction Document, in each case as of the date hereof.

 

 

    	 

    	 

    

 

This
letter agreement (this “Letter Agreement”) confirms our recent discussions about, among other matters, certain modifications
to the 2021 Senior Secured Convertible Notes and the 2022 Purchase Agreement.

 

	 	(1)	This
    Letter Agreement shall be deemed to be a 2021 Transaction Document and a 2022 Transaction Document;
	 	 	 
	 	(2)	The
    outstanding balance, if any, on the 2021 Senior Secured Convertible Notes shall become due and payable on October 10, 2022, unless
    further extended by the Parties, at which time such outstanding balance shall be satisfied in cash.
	 	 	 
	 	(3)	The
    Conversion Price and Floor Price of the 2021 Senior Secured Convertible Notes which remain outstanding as of even date hereof shall
    be $0.23, such Conversion Price to become effective as of the date of this Letter Agreement and apply through September 30, 2022;
	 	 	 
	 	(4)	The
    reduction in Conversion Price and Floor Price of the 2021 Senior Secured Convertible Notes effected pursuant to this Letter Agreement
    does not constitute a Dilutive Issuance or require an adjustment of the Floor Price (other than solely to effect paragraph (3)) or
    Conversion Price under the Transaction Documents. 

 

The
Company hereby agrees, for itself and its Subsidiaries, that the Guarantors continue to guaranty, pursuant to the Guaranty, as primary
obligor and not as surety, the full and punctual payment when due of the obligations owing under the Notes and the other Transaction
Documents as modified hereby (as limited by the original terms of the Guaranty) and that the terms hereof shall not affect in any way
their obligations and liabilities, as expressly modified hereby, under the Transaction Documents. The Company, for itself and its Subsidiaries,
hereby reaffirms (a) all such obligations and liabilities and agrees that such obligations and liabilities shall remain in full force
and effect and (b) the security interests granted under the Transaction Documents and agrees that such security interests shall continue
to secure such obligations and liabilities.

 

This
Letter Agreement is a Transaction Document and is limited as written. As of the date first written above, each reference in the Purchase
Agreement or any other applicable Transaction Document to “this Agreement,” “hereunder,” “hereof,”
“herein,” or words of like import, and each reference in the other Transaction Documents to such Purchase Agreement
or other Transaction Documents (including, without limitation, by means of words like “thereunder,” “thereof”
and words of like import), shall refer to the Purchase Agreement as modified thereby, and this Letter Agreement and the Purchase Agreement
shall be read together and construed as a single agreement. The execution, delivery and effectiveness of this Letter Agreement shall
not, except as expressly provided herein, (A) waive or modify any right, power or remedy under, or any other provision of, any Transaction
Document or (B) commit or otherwise obligate any Purchaser to enter into or consider entering into any other amendment, waiver or modification
of any Transaction Document.

 

All
communications and notices hereunder shall be given as provided in the Transaction Documents. This Letter Agreement (a) shall be governed
by and construed in accordance with the law of the State of Nevada, (b) is for the exclusive benefit of the parties hereto and the other
Purchasers and beneficiaries of the Purchaser Agreement and, together with the other Transaction Documents, constitutes the entire agreement
of such parties, superseding all prior agreements among them, with respect to the subject matter hereof, (c) may be modified, waived
or assigned only in writing and only to the extent such modification, waiver or assignment would be permitted under the Transaction Documents
(and any attempt to assign this Letter Agreement without such writing shall be null and void), (d) is a negotiated document, entered
into freely among the parties upon advice of their own counsel, and it should not be construed against any of its drafters and (e) shall
survive the satisfaction or discharge of the amounts owing under the Transaction Documents. The fact that any term or provision of this
Letter Agreement is held invalid, illegal or unenforceable as to any person in any situation in any jurisdiction shall not affect the
validity, enforceability or legality of the remaining terms or provisions hereof or the validity, enforceability or legality of such
offending term or provision in any other situation or jurisdiction or as applied to any person.

 

 

    	 

    	 

    

 

This
Letter Agreement is expressly conditioned on the Company’s Board of Directors approving this Letter Agreement and all undertakings
thereto in all respects and providing written evidence of the same to the Investors by September 20, 2022.

 

Kindly
confirm your agreement with the above by signing in the space indicated below and by PDFing a partially executed copy of this letter
to the undersigned, and which may be executed in identical counterparts, each of which shall be deemed an original but all of which shall
constitute one and the same agreement. 

 

	 	Very truly yours,
	 	 	 
	 	ENSYSCE BIOSCIENCES, INC.
	 	 	 
	 	By:
    	/s/
    Lynn Kirkpatrick 
	 	 	Dr.
    Lynn Kirkpatrick
	 	 	Chief
    Executive Officer

 

	AGREED AND ACCEPTED:	 
	 	 	 
	3i, LP	 
	 	 	 
	By:	/s/
    Maier Tarlow	 
	Name:	Maier
    Tarlow	 
	Title:
    	Manager
    On Behalf Of The GP	 

 

	Anson Investments Master Fund LP	 
	 	 	 
	By:	/s/
    Amin Nathoo 	 
	Name:
    	Amin
    Nathoo	 
	Title:
    	Director,
    Anson Advisors Inc.	 

 

	Anson
    East Master Fund LP	 
	 	 	 
	By:	/s/
    Amin Nathoo 	 
	Name:
    	Amin
    Nathoo	 
	Title:
    	Director,
    Anson Advisors Inc.Exhibit 10.1

 

 

PRIVATE & CONFIDENTIAL

 

VIA E-MAIL

September 16, 2022

 

Conor McCarthy

conor_mccarthy@yahoo.com

 

Dear Conor:

 

As discussed, your employment
with Ideanomics, Inc. (“Ideanomics” or the “Company”) will end effective September 16, 2022 (the “Separation
Date”), which shall be deemed a termination by the Company without Cause (as defined in the Employment Agreement and the Plan).
Accordingly, your eligibility for participation in the Company’s health benefits program and other benefits programs will end on
September 30, 2022. You will receive instructions in the mail regarding how you may continue to receive health benefits, if eligible,
your Separation Date.

 

Below is a Separation Agreement
and General Release (“Agreement”) to resolve all matters between you and Ideanomics, its divisions, officers, directors, employees
and affiliates. Please take your time to thoroughly review and understand the effect of this Agreement.

 

Prior Employment Agreement

 

The Company and you acknowledge
your employment letter agreement dated July 31, 2020 (the “Employment Agreement”), a copy of which is incorporated herein
by reference. Unless otherwise stated, all capitalized terms herein have the same meaning as defined within the Employment Agreement.

 

Transition Period

 

During the period from September
12, 2022 to September 16, 2022 (“Transition Period”), you will work with Stephen Johnston, to transition your duties as Chief
Financial Officer to him.

 

Payments as Consideration in Exchange for Your
Promises

 

The Company shall pay you
your annual gross base salary and provide you benefits owed, and pay you for all accrued but unused vacation and any unreimbursed expenses,
through the Separation Date. In accordance with and subject to terms of Section 4 of the Employment Agreement, the Company shall provide
you the following monetary benefits in exchange for your release of claims and your other promises described in this Agreement:

 

1441 Broadway, Suite #5116,
New York, NY 10018 | www.ideanomics.com

 

     

     

    

 

 

		1.	The Company shall pay you a lump sum cash payment of $525,000 no later than ninety (90), but no earlier
than thirty-one (31), days following your Separation Date.

 

		2.	The Company shall pay you a sum of $175,000, which is the remainder of your prior year’s performance
bonus no later than the second payroll date following the date of this agreement.

 

		3.	The Company shall pay you the cost of continuing your health insurance benefits pursuant to COBRA, if
eligible, for a period of twelve (12) months, estimated to be $24,000.

 

All payments provided to you
pursuant to this Agreement shall be less mandatory withholdings and deductions and distributed in accordance with the Company’s
regular payroll practices. You acknowledge that you would not otherwise be entitled to one or more of the benefits described above without
signing this Agreement and that such benefits: (i) are adequate consideration in exchange for your release of claims and other promises
herein; and (ii) fully satisfy all claims for compensation that you may have against the Company, including without limitation any claim
for back pay, front pay, vacation pay, paid time off, bonuses, fringe benefits, expense reimbursements, or other forms of compensation
of any kind that are not otherwise set forth within this Agreement other than vested benefits, indemnification, advancement, and insurance
coverage.

 

Stock Options

 

You and the Company agree
and hereby acknowledge that over the course of your employment pursuant to 3 separate stock option agreements dated May 8, 2020 and July
31, 2021 (the “Stock Options Agreements”), the Company has granted you the option to purchase an aggregate of 2,250,000 shares
of the Company’s Common Stock (the “Options”), subject to the terms and conditions of your Stock Options Agreements
governing the Options and the Ideanomics, Inc. Amended and Restated 2010 Equity Incentive Plan (the “Plan”). The vesting schedules
and exercise prices of Your Options are defined in your Stock Options Agreements and summarized as follows:

 

		1.	1,500,000 of the Options are fully vested and exercisable at $0.53 per share.

 

		2.	437,500 of the Options are fully vested and exercisable at $2.37 per share.

 

		3.	312,500 of the Options are not yet vested and will vest at a rate of 1/18th per month over
the next 18 months and are exercisable (once vested) at $2.37 per share.

 

Subject to all of the provisions of your
Stock Options Agreements, to the extent vested, the Options will be exercisable for twelve (12) months after you cease employment on
September 16, 2022. To the extent not yet vested, the Options will be exercisable for twelve (12) months after they vest.

 

     

     

    

 

Further, you and the Company agree and hereby
acknowledge that you own 290,062 of the original amount of 625,000 Restricted Shares granted to you by the Company on July 23, 2021, subject
to all of the provisions of your Restricted Shares Grant Agreement and the Plan.

 

To the extent not prohibited by Section 402 of
the Sarbanes-Oxley Act of 2002, you will be permitted to pay the exercise price and any tax withholding required in connection with the
exercise of your stock options in accordance with any broker-assisted cashless exercise procedures (including without limitation “Sell
to Cover” or “Same Day Sale/Cash” Exercise) approved by the Company.  You agree to be responsible for the tax consequences
that may apply to you as the result of such permission and any such exercise.

 

General Release of Claims

 

In consideration of the
payments and benefits to you provided herein, you agree to and hereby release and discharge the Company, its parents, subsidiaries,
affiliated companies and entities and their successors or assigns, divisions, directors, officers, managers, shareholders, founders,
partners, limited partners, members, agents, consultants, contractors, payroll companies, insurers, licensees, attorneys,
representatives and employees, past and present (collectively “Releasees”) from any and all claims, causes of action,
arbitrations and demands, whether known or unknown, which you have or ever have had, which are based on acts or omissions occurring
up to and including the date this Agreement is fully executed, except as to: (i) the enforcement of this Agreement; (ii) vested
benefits; (iii) any rights to indemnification and/or advancement (including without limitation pursuant to law as well as the Articles of Incorporation of Alpha Nutraceuticals, Inc.) and, for the avoidance of doubt, the
Company will: (1) continue to indemnify you and advance your expenses with respect to the investigation of the Company by the U.S.
Securities and Exchange Commission for which you are being represented by Wilmer Cutler Pickering Hale and Dorr LLP; and (2) provide
you indemnification and advancement on terms no less favorable than similarly situated executives); (iv) rights as an equity holder
of the Company; (v) any right to insurance coverage; and (vi) any rights which cannot be waived as a matter of law. In this release,
you further release the Company and its parents, subsidiaries and affiliated entities from any and all compensation owed to you,
including vacation pay and any attorneys’ fees, damages and costs you could recover under any statute or common law theory,
except as otherwise provided herein. Included within this release, without limiting its scope, are claims arising out of your
employment or the termination of your employment based on Title VII of the Civil Rights Acts of 1964, the Americans with
Disabilities Act of 1990, the Age Discrimination in Employment Act (“ADEA”), the Older Workers Benefit Protection Act,
the Worker Adjustment and Retraining Notification (“WARN”) Act (and any state or local WARN laws, as applicable), the
Fair Labor Standards Act of 1938, the Equal Pay Act of 1963, the Family and Medical Leave Act, the Employee Retirement Income
Security Act of 1974, the Civil Rights Act of 1991, the Genetic Information Nondiscrimination Act of 2008, the Lilly Ledbetter Fair
Pay Act of 2009, the Sarbanes-Oxley Act of 2002, the Dodd–Frank Wall Street Reform and Consumer Protection Act, as all such
laws have been amended from time to time, or any other federal, state, or local human rights, civil rights, disability,
discrimination, retaliation, wage and hour, sick leave, fair employment practices or labor laws, or any theory of contract,
criminal, arbitral or tort law (collectively “Claims”). By signing this Agreement, you acknowledge and represent that
you have suffered no injuries or occupational diseases relating to or arising out of your employment with the Company and that you
have received all wages and leave to which you were entitled as an employee of the Company. Further, by signing this Agreement, you
also expressly acknowledge and represent that you have been correctly paid for all time worked and that you are not currently aware
of any facts or circumstances constituting a violation of the Fair Labor Standards Act, the Equal Pay Act, or any other applicable
state or local wage and hour laws. You specifically acknowledge that you release and waive any right to attorneys’ fees, costs
and expenses associated with any of the released Claims except as otherwise provided herein.

 

     

     

    

 

In consideration of the release
and benefits to the Releasees provided herein, the Releasees agree to and hereby release and discharge you, your heirs, executors, administrators,
agents, assigns, successors, and representatives from any and all known claims, causes of action, arbitrations and demands which the Releasees
have or ever have had, which are based on acts or omissions occurring up to and including the date this Agreement is fully executed, except
as to: (i) the enforcement of this Agreement; and (ii) any rights which cannot be waived as a matter of law. The Releasees specifically
acknowledge that they release and waive any right to attorneys’ fees, costs and expenses associated with any of the released known
claims except as otherwise provided herein.

 

Confidential Information

 

You acknowledge that, as a
result of your employment, you have been provided access to Confidential and/or Proprietary Information related to the Company and the
Company’s customers, merchants, vendors, licensees and suppliers. For purposes of this Agreement, “Confidential and/or Proprietary
Information” includes, without limitation, the following types of non-public information: (i) the identities, contact information,
purchasing patterns, specifications, and preferences of the Company’s customers, merchants, vendors, licensees and suppliers; (ii)
actual and proposed contracts or contractual terms between the Company and the Company’s customers, merchants, vendors, licensees
and suppliers; (iii) negotiation histories and pricing policies; (iv) methods of operation; (v) computer programs; (vi) financial information
such as sales, profit, and cost data; (vii) licensing information; (viii) sourcing, merchandising, and manufacturing information; (ix)
marketing strategies and sales promotion activities; (x) information processing standards and practices; (xi) personnel information such
as employees’ compensation, benefits, skills, qualifications, and abilities, as well as the Company’s staffing plans, strategies,
and training programs; (xii) any other information qualifying as a trade secret under applicable state trade secret law; and (xiii) any
other information which you have been told is confidential by either the Company or the Company’s customers, merchants, vendors,
licensees or suppliers.

 

You promise you will
not, directly or indirectly, at any time after your separation from employment with the Company, except as required by law: (i) use
any Confidential and/or Proprietary Information for any purpose; (ii) disclose any Confidential and/or Proprietary Information to
any person or entity other than the Company; or (iii) retain possession of any Confidential and/or Proprietary Information. By
signing this Agreement, you warrant that you have not disclosed any Confidential and/or Proprietary Information to any person or
entity not affiliated with the Company at the time of such disclosure. You further warrant that, as of the date of your signature
hereon, you have returned to the Company (or, in the case of electronic information, destroyed) any and all documents, files, notes,
memoranda, databases, computer files, computer programs, and Confidential and/or Proprietary Information related in any way to the
Company, or alternatively, you agree that you will return and/or destroy such information and materials before you accept any
benefit pursuant to this Agreement.

 

Notwithstanding your confidentiality
obligations set forth above, you shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a Confidential and/or Proprietary Information that is made: (i) in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii)
in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

     

     

    

 

Non-Disparagement

 

You further agree you will
not make any statements or comments of a defamatory or disparaging nature to third parties regarding the Company or its officers, directors,
personnel or products, or those of its affiliates except as necessary to enforce this Agreement. This prohibition against defamatory or
disparaging remarks includes, without limitation, statements to any individual or entity which would be reasonably likely to affect adversely
the Company’s business. Notwithstanding the foregoing, nothing herein is intended to prevent you from testifying in good faith under
oath pursuant to a subpoena or as otherwise required by law.

 

The Company’s
Chief Executive Officer and direct reports will not make any statements or comments of a defamatory or disparaging nature to third
parties regarding you except as necessary to enforce this Agreement. This prohibition against defamatory or disparaging remarks
includes, without limitation, statements to any individual or entity which would be reasonably likely to affect you adversely.
Notwithstanding the foregoing, nothing herein is intended to prevent the aforementioned individuals from testifying in good faith
under oath pursuant to a subpoena or as otherwise required by law.

 

Non-Competition and Non-Solicitation Covenants

 

You acknowledge the validity
of your non-competition and non-solicitation promises set forth in Sections 7 and 8 the Employment Agreement (the “Non-Competition
Promise” and Non-Solicitation Promises”). In exchange for your benefits pursuant to this Agreement, you promise to comply
with the Non-Competition and Non-Solicitation Promises and you waive any claim or rights to challenge the enforceability of such promises.
You acknowledge and agree that your compliance with the Non-Competition and Non-Solicitation Promises is a material inducement for the
Company’s execution of this Agreement, without which the Company would not agree to provide you the benefits described herein. For
the avoidance of doubt, the Non-Competition and Non-Solicitation Promises are effective through September 15th, 2023. Accordingly, in
the event the Company has reasonable grounds to conclude that you have breached any of the Non-Competition and Non-Solicitation Promises,
you agree that: (i) the Company may cease paying any of the monetary benefits owed to you pursuant to this Agreement; (ii) you shall be
obligated to return to the Company ninety percent (90%) of the gross amount of any payments that you have received pursuant to this Agreement;
and (iii) all other terms of this Agreement, including your release of claims, shall remain in full force and effect.

 

     

     

    

 

Non-Admission of Liability

 

You acknowledge that nothing
in this Agreement shall be viewed or construed as an admission of fault, liability, or wrongdoing of any kind on behalf of the Company.

 

Voluntariness of Agreement

 

By signing this Agreement,
you understand, warrant, and acknowledge: (i) you are not suffering from any disability or impairment which could render you unable to
read, consider, or understand this Agreement; (ii) you have carefully read and fully understand all of the terms of this Agreement; (iii)
you are freely and voluntarily entering into this Agreement under which you shall release the Company as described above in exchange for
the benefits to you described above; (iv) you are not relying and have not relied upon any representations or statements from any of the
Company’s agents or attorneys with regard to the subject matter of this Agreement; and (v) the Company advised you that you may
consult with an attorney of your choice and at your expense regarding the terms of this Agreement before you sign below.

 

Review and Revocation Periods

 

As
described above, your general release of claims includes a waiver of all rights and claims you may have under the Age Discrimination in
Employment Act of 1967, as amended (29 U.S.C. §§ 621 et seq.) (“ADEA”). You acknowledge that you have at
least twenty-one (21) days to review and consider whether to sign this Agreement and that such period of time is reasonable. You may decide
to unilaterally waive this twenty-one (21) day review period by signing below beforehand. On September 19, 2022, the Company may revoke
the offer in this Agreement unless you have delivered a signed version of this Agreement to the Company beforehand (notwithstanding anything
to the contrary in the Employment Agreement).

 

You may revoke your release
of claims under the ADEA at any time within seven (7) days of your execution of this Agreement. Your release of claims under the ADEA
shall not become effective or enforceable until this seven (7) day revocation period has expired without you having exercised your right
to revoke your release of claims under the ADEA. Any revocation you make must be submitted via a signed letter delivered to the Company
at the following address no later than the seventh (7th) day following your execution of this Agreement: Ideanomics, Inc., Attn: Alfred
Poor, CEO: 1441 Broadway, Suite #5116, New York, NY 10018. Accordingly, the “Effective Date” of this Agreement shall be
the eighth (8th) day following your execution of this Agreement. If you do not exercise your right to revoke your release of claims under
the ADEA during the revocation period, this entire Agreement will take effect as of the Effective Date. On the other hand, if you duly
revoke your claims under the ADEA during this revocation period, this entire Agreement will take effect as of the date of your revocation,
except for your release of claims under the ADEA, and in such case you shall waive your rights to the benefits described above and, instead,
shall only be entitled to payment of $500.00, less all applicable deductions and withholdings.

 

Entire Agreement

 

You acknowledge that this
Agreement, the Stock Option Agreements, the Restricted Shares Grant Agreement, the Plan, and the Employment Agreement, which are incorporated
herein by reference and, in some cases as provided herein, modified, contain the entire agreement and understanding between you and the
Company regarding the subject matter herein and that they supersede all prior negotiations and all agreements, proposed or otherwise,
whether written or oral, concerning the subject matter described herein. This is an integrated document. No prior drafts or versions of
this Agreement may be used for purposes of interpreting this Agreement. This Agreement shall not be deemed to have been prepared or drafted
by one party or the other, and you further agree that no ambiguities herein shall be construed against a party hereto solely because it
drafted this Agreement. With respect to your obligations concerning confidential information, the Non-Competition and Non-Solicitation
Promises, and non-disparagement, to the extent there is a conflict between an obligation within this Agreement and the Employment Agreement,
the broader obligation shall control.

 

     

     

    

 

Severability

 

You acknowledge that the
scope of the post-employment restrictions set forth herein are as narrowly tailored as possible to protect the Company’s
legitimate interests, including its interests pertaining to the Company’s Confidential and/or Proprietary Information,
customer goodwill, and investment in its workforce. You and the Company agree that this Agreement is intended to be enforced to the
fullest extent possible under applicable laws and public policies. Accordingly, if any term of this Agreement is declared illegal or
unenforceable by any court of competent jurisdiction, such provision or portion shall be deemed modified so as to render it
enforceable. To the extent such provision or portion of this Agreement cannot be rendered enforceable, the invalid provision or
portion will be considered not to be part of the Agreement, and the remainder shall continue in force and effect.

 

Choice of Law

 

This Agreement shall be governed
by the laws of the State of New York without regard to such State’s choice of law principles.

 

Dispute Resolution

 

Pursuant to Section 14 of
your Employment Agreement, should any dispute arise between you and the Company or any Company affiliate regarding your separation from
the Company, you and the Company or the Company affiliate will confer in good faith to promptly resolve such dispute. In the event that
you and the Company or the Company affiliate are unable to resolve the dispute, and should either party to the dispute desire to pursue
a claim against the other party, both you and the Company or the Company affiliate agree to have the dispute resolved by final and binding
Arbitration held in New York County, New York. The Arbitration shall be conducted by JAMS or the American Arbitration Association and
provided by an impartial third-party Arbitration provider in accordance with the employment dispute rules then in effect. All previously
unasserted claims arising under federal, state, or local statutory or common law and all disputes relating to the validity of this contract,
as well as this Arbitration provision, shall be decided by binding and final arbitration. Any award of the Arbitrator(s) is final and
binding, and may be entered as a judgment in any court of competent jurisdiction. The prevailing party shall be entitled to reimbursement
of his/its related costs, including reasonable attorneys’ fees, from the non-prevailing party. Notwithstanding the foregoing, nothing
in this letter shall prohibit either party from applying to a court of competent jurisdiction (instead of an arbitrator) for injunctive
relief to enjoin an actual or threatened breach of each other’s obligations set forth in this letter.

 

Miscellaneous

 

This Agreement may be executed
in electronic counterparts, and a signed copy of this Agreement may be treated as a signed original for purposes of enforcement.

 

If you agree to the terms
of this Agreement, please sign (via e-signature or regular signature) and return to me. If you sign via e-signature, your signature will
be automatically delivered. If you sign on the hard copy of the Agreement, send a signed copy of the Agreement to Alfred Poor, CEO: alf.poor@ideanomics.com
on or before twenty-one (21) days from the date you were presented with this Agreement. If you would like to make other arrangements
for providing the signed Agreement, please contact Mr. Poor at the email address above. 

 

     

     

    

 

Thank you for your contributions to the Company.

 

Sincerely,

 

Alfred P. Poor

CEO

 

Ideanomics, Inc.

 

	By:	/s/ Alfred P. Poor	 	/s/ Conor McCarthy
	 	 	 	 
	 	Alfred P. Poor	 	Conor McCarthy
	 	 	 	 
	 	CEO	 	 
	 	 	 	 
	Date:	19-Sep-2022 | 3:01 PM PDT	 	Date:	9/19/2022

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]